Company Updates
LAA Signs MotorCredit Agreement with Credito Real
LatAm Autos Limited (ASX: LAA) has announced the agreement with Credito Real to launch the LatAm Auto’s MotorCredit product in Mexico, after an initial trial period.
Octagon Strategy – the Case for Investors Sticking out the Volatility in Bitcoin and Ethereum
During the Month of May, a price correction for bitcoin wiped off nearly $4 billion in its market value.
Brauz CEO Talks to the Australian About Amazon Opportunities, Expansion & $1.25m Capital Raised
Brauz, CEO, Lee Hardham – a former advertising executive of News Corp, has spoken out of the benefits with Amazon with about 50 per cent of retail stores not having an online presence.
Wholesale Investor – Managing Director’s Update
Welcome to our first edition of our Quarterly Update for Wholesale Investor for Q4 of FY17.
Carbon Trade eXchange & UNFCCC Partner to strengthen the UN’s Climate Neutral
The UNFCCC and Carbon Trade eXchange (CTX) have recently announced a collaboration to strengthen the UN’s Climate Neutral initiative.
Crowd Mobile Reports Record Fourth Quarter with $11.6m in Revenue & $3.3 EBITDA
Crowd Mobile Limited (ASX: CM8) has recently announced the Fourth Quarter results for the three months ended 30 June 2017. Record quarterly revenue has supported the company’s strong FY17 performance.
iSentric Limited Acquires My Play Company Limited
iSentric Limited (ASX: ICU) has recently announced a Sale and Purchase Agreement for the acquisition of My Play Company Limited. The Term Sheet for the MyPlay acquisition was announced on the 23rd Mar
TEHO: Pulling strong in the mooring line industry
TEHO International is a global, diversified holding company specialising in marine, offshore O&G and real estate industries. The company has been listed on the Singapore Stock Exchange since June 2009
DMX-200 Phase 2a trial meets primary end point for Chronic Kidney Disease
DMX-200 is an adjunct therapy in which patients who are already on the standard of care angiotensin II type I receptor blocker (irbesartan) are also dosed with a chemokine receptor CCR2 blocker.
Backed By Leading Investment Groups and Family Offices
